Lycia Therapeutics, Inc. Stock

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. Its immunoglobulin E (IgE) portfolio consists of LCA-0061 and LCA-0062, which are both designed to efficiently degrade IgE for the treatment of allergic diseases, including food allergies. The LCA-0061 is an antibody-small molecule conjugate cataLYTAC degrader designed to target and degrade IgE, a known driver of multiple allergic diseases, including food allergy, allergic asthma, allergic rhinitis, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps. The LYTAC platform serves as a drug discovery engine. It produces protein-degrading therapeutics that target extracellular proteins and shuttle them from outside the cell into the lysosome, where they are degraded.